AUS
NZ
UK
CA
USA
IND
Summary
- Mesoblast’s Remestemcel-L (RYONCIL™) for pediatric patients with Steroid-refractory Acute Graft Versus Host disease recently receives overwhelming favour by Oncologic Drugs Advisory Committee of FDA.
- Tyro Payments processed transactions worth over $11.1 billion in value in the first half of FY20 for more than 32,000 merchants in Australia that are partnered with Tyro
- The performance of Whispir Limited over the fourth quarter strengthened due to the pandemic-driven demand-rise for communications software and stakeholder engagement by both new and existing customers.
The investment priorities with the onset of the pandemic have been significantly slanted towards a conservative approach, with investors’ interest in risky assets somersaulting. However, the transforming landscape and the turn of events with the economic reopening has brewed fresh momentum as investors riffle through opportunities keeping a watch on the share price movement.
In the current scenario, while many investors appear to go bonkers over the shares promising strong potential in COVID-19 setting, the others continue to ponder over unravelling the right time to invest in the right stocks.
ALSO READ: Three Unique Investment Tips to Build Recession-Proof Portfolio in COVID-19 Crisis
As Aussies adapt to the new normal, many investors seem to earmark significant funds to ward off the impending chances of personal financial crunches in the future. As per the Australian Bureau of Statistics (ABS), the full-time adult average weekly ordinary time earnings in May 2020 was $1,713.90, bringing the average annual earnings to $89,123. Setting aside 10-12% of the total annual earnings of approximately $10,000 on an average can go a long way in mitigating financial risks while also ensuring that personal obligations and endeavours are carried out smoothly.
However, the dilemma concerning investments continues for many who yet try to uncover the lucrativeness of the shares that remained under investors radar. Let us cast an eye over some stocks which off lately has captivated investor’s attention and explore the future promises such shares hold.
Mesoblast Limited
The share price of Mesoblast Limited (ASX:MSB) edged up by around 46% in the past one month and 65.5% in the last six months. The recent MSB stock movement suggests that $10,000 investment in its shares one month back would now have been $14,600. The significant popularity of MSB shares is riding on the back of its latest endeavours in Covid-19 vaccine development. Significantly, MSB stock closed at $4.910 per share on 17 August 2020, up by over 4.468% intraday.
In the latest update, Mesoblast indicated Oncologic Drugs Advisory Committee (ODAC) of the United States Food and Drug Administration (FDA) voted in great majority in favour of Remestemcel-L (RYONCIL™) for its efficacy in pediatric patients with Steroid-refractory Acute Graft Versus Host disease.
The Company’s lead product candidate, RYONCIL (remestemcel-L), is an investigational therapy, which comprises of culture-expanded mesenchymal stem cells that are derived from an unrelated donor’s bone marrow and administered in a series of infusions.
ALSO READ: Mesoblast Share Price Goes Berserk: Investors had a Sunny Day
RYONCIL - down-regulates pro-inflammatory cytokines production, increases anti-inflammatory cytokines production and enables recruitment of naturally occurring anti-inflammatory cells to involved tissues. RYONCIL believed to have immunomodulatory properties and uses the above process to counteracts the inflammatory processes that are implicated in steroid-refractory acute graft versus host disease.
The outlook for Mesoblast includes:
- Biologics License application of Mesoblast seeking the approval for its product candidate RYONCIL™ for steroid-refractory acute graft versus host disease in children has been accepted for priority review by FDA. If approved, the product is expected to be launch in the US in 2020.
- Remestemcel-L for other inflammatory diseases in children and adults is also being developed by the Company and includes moderate to severe acute respiratory distress syndrome.
- Mesoblast is completing phase 3 trials for its product candidates for advanced heart failure and chronic low back pain.
Tyro Payments Limited
The technology-focused and values-driven company, Tyro Payments Limited (ASX:TYR) offers Australian businesses with simple, flexible and reliable payment solutions as well as value-enhancing complementary business banking products.
The Company processed over $11.1 billion in transaction value in the first half of FY20 from over 32k Australian merchants who partnered with Tyro. It has generated revenue of $117.3 million, originated loans worth $37.4 million and holding merchant deposits totalling $39.7 million.
The digitals payments saw a rise in the significant popularity with the eCommerce trends picking up the momentum. Transaction value in FY2020 increased by 15% from $17.497 billion in FY19 to $20.131 billion in FY20.
Source: TYR ASX Update
Tyro payments saw its share price slump by ~7% in the past one months and 3.7% on the year-to-date basis. TYR stock on 17 August 2020 closed the day’s trade at $3.410.
Whispir Limited
The software-as-a-service (SaaS) communication platform provider, Whispir Limited (ASX:WSP) automates interactions between organisations and people, ensuring the flow of accurate, timely and useful information between stakeholders. The remote work trends have accelerated the demand for communication solutions for ensuring smooth flow of the operations.
ALSO READ: Casting an eye on the IT stock that is knocking the charts: CAT
The Company’s performance over the fourth quarter ending 30 June 2020 strengthened owing to the rise in the demand for communications software and stakeholder engagement during the COVID-19 pandemic by both new as well as existing customers.
The positive spin-offs in the fourth quarter for the company comprised higher transaction volumes from existing customers, maintenance of strong cost management and recording net new customers. The positive results of the company include:
- Annualised Recurring Revenue rose by 35.7% to $42.2 million compared to the prior-year corresponding period. In comparison, there was an increase of 4.2% on the March quarter, driven by growth in ANZ and Asia.
- Quarterly customer cash receipts worth $11.3 million was up by 27% on the previous quarter and 36.5% on the prior corresponding period.
- Record customer growth in the second quarter, with the acquisition of 72 new customers during the quarter.
- For Q4 FY20, net cash used in operating activities saw a continued reduction, dipping by 93% on the previous quarter to $0.1 million.
The Company’s management believes that WCaaS market may reach US$8 billion in 2024, providing Whispir and its offerings deliver strong growth prospects.
Source: WSP ASX Update
WSP share price has marked an uptick of 23% in the past one month, while the share price has soared by over 156% on the year-to-date basis. It indicates the investment worth $10,000 would be $12,300 after one month of investment. As on 17 August 2020, WSP stock ended the day at $4.29, up by over 7% intraday.
